QTRX News & Events

Quanterix "announced that Vandana Sriram, its CFO will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition."

Reports Q1 revenue $36.4M, consensus $36.84M. The company said, ""We continue to make progress toward achieving cash flow breakeven as we move into a phase of growth now that we have captured the cost synergies from the Akoya acquisition. As part of this process, we are focusing our investment into areas that will benefit our commercial effectiveness and drive improved operating results in 2026 and beyond. Additionally, our Alzheimer's diagnostics business continues its rapid growth with several key milestones expected in the second half of this year, including the completion of three clinical utility studies and a decision from the FDA on our 510(k) application."

The company said, "Quanterix is reaffirming its guidance for 2026. The Company expects revenues of $169 to $174 million, which assumes no underlying improvement in the academic or pharmaceutical end markets. Quanterix anticipates GAAP gross margin of 41% to 45%, and adjusted gross margin (non-GAAP) of 49% to 53%. In the first quarter, Quanterix changed its accounting policy for classifying shipping and handling costs for product sales to record them within gross margin. Historically, these costs were recorded in selling, general and administrative expenses. This reclassification is reflected in the Company's GAAP guidance range, but there is no change to the non-GAAP margin expectation. Quanterix continues to anticipate achieving cash flow breakeven in the second half of the year and expects to end the year with cash in the range of $100M, and no debt."